CME (CME) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
CME Group Inc. (CME) insider buying and selling: 5 purchases, 17 sales
136 Form 4 Table I transactions filed with the SEC by CME Group Inc. insiders between 2025-08-26 and 2026-09-28 (15-month history): 5 open-market purchases and 17 sales, plus 114 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $10.4M by Duffy Terrence A on 2026-05-15.
CME insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, CME insiders filed 4 purchases worth $667k and 13 sales worth $30.1M on the open market. The net balance is on the sell side: $29.4M more sold than bought.
The biggest buyer was Shepard William R (Director): $667k in 4 purchases, the only buyer. The biggest seller was Duffy Terrence A (Chairman and CEO): $21.3M in 3 sales, out of 10 different sellers.
The largest trade of the period was a sale of $10.4M on May 15, 2026, by Duffy Terrence A (Chairman and CEO). Form 4 on sec.gov (0001212809-26-000004).
Of the 13 sales, 1 (8%, $1.1M) carries the 10b5-1 plan flag on the Form 4, meaning it was scheduled months ahead; the other 12 do not.
The last three months show 1 purchase and 2 sales, against 1 and 2 in the three before. The latest purchase is from Sep 25, 2026; the latest sale from Sep 14, 2026.
Against its sector (Financial Services, 70 companies with an insider page on this site), over the same dates the median is 10 sales and 0 purchases on the open market. CME has more sales than 41 of the other 69, ranks 28 of 70 by net dollars sold, and 32 of the 70 have at least one purchase, CME included.
The 20 most important trades
The 5 open-market purchases first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 136 CME trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-03-26 | 2026-03-30 | Shepard William R | Director | $437k | P — Open-market purchase Indirect holding, through: by Trust Form 4 footnoteF1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker. Actual amounts of fractional shares owned may vary slightly due to rounding. | SEC |
| 2026-09-25 | 2026-09-28 | Shepard William R | Director | $79k | P — Open-market purchase Indirect holding, through: by Trust Form 4 footnoteF2 Represents shares acquired pursuant to a broker-administered dividend reinvestment plan. | SEC |
| 2026-06-25 | 2026-06-29 | Shepard William R | Director | $78k | P — Open-market purchase Indirect holding, through: by Trust Form 4 footnoteF3 Represents shares acquired pursuant to a broker-administered dividend reinvestment plan. | SEC |
| 2025-12-30 | 2026-01-02 | Shepard William R | Director | $73k | P — Open-market purchase Indirect holding, through: by Trust Form 4 footnoteF1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker. Actual amounts of fractional shares owned may vary slightly due to rounding. | SEC |
| 2025-09-25 | 2025-09-26 | Shepard William R | Director | $73k | P — Open-market purchase Indirect holding, through: by Trust Form 4 footnoteF1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker. Actual amounts of fractional shares owned may vary slightly due to rounding. | SEC |
| 2026-05-15 | 2026-05-18 | Duffy Terrence A | Chairman and CEO | $10.4M | S — Open-market sale2 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $298.00 to $298.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $299.00 to $299.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. | SEC |
| 2025-12-11 | 2025-12-15 | Duffy Terrence A | Chairman and CEO | $6.7M | S — Open-market saleForm 4 footnoteF1 On December 11, 2025, Mr. Duffy sold an aggregate of 25,000 shares of CME Group Class A common stock. For reporting purposes, the sale prices within $1 range have been aggregated and the weighted average has been reported. The price range was $268.66 to $269.66 for 13,809 shares and $269.68 to $270.51 for 11,911 shares. The Company maintains a record of the transaction and copies will be provided upon request. | SEC |
| 2026-09-10 | 2026-09-11 | Duffy Terrence A | Chairman and CEO | $4.1M | S — Open-market sale2 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.875 to $274.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.9056 to $275.0804, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. | SEC |
| 2025-08-26 | 2025-08-26 | Cutinho Sunil | Chief Information Officer | $3.2M | S — Open-market sale2 Form 4 footnotesF1 On August 26, 2025, Mr. Cutinho sold an aggregate of 5930 shares of CME Group Class A common stock. For reporting purposes, the sale prices within $1 range have been aggregated and the weighted average has been reported. The price range was $271.69 to $272.58. The Company maintains a record of the transaction and copies will be provided upon request. F2 On August 26, 2025, Mr. Cutinho sold an aggregate of 5966 shares of CME Group Class A common stock. For reporting purposes, the sale prices within $1 range have been aggregated and the weighted average has been reported. The price range was $270.32 to $271.21. The Company maintains a record of the transaction and copies will be provided upon request. | SEC |
| 2025-11-20 | 2025-11-21 | Sammann Derek | Sr MD Gl Hd Commodities Mkts | $2.0M | S — Open-market sale Indirect holding, through: by Trust; by Spouse | SEC |
| 2026-05-18 | 2026-05-19 | Piell Hilda Harris | Sr MD & Chief HR Officer | $1.8M | S — Open-market sale | SEC |
| 2026-03-12 | 2026-03-12 | Vroman Ken | Chief Transformation Officer | $1.6M | S — Open-market saleForm 4 footnoteF1 On March 12, 2026, Mr. Vroman sold an aggregate of 5160 shares of CME Group Class A common stock. For reporting purposes, the sale prices within $1 range have been aggregated and the weighted average has been reported. The price range was $308.969 to $309.11. The Company maintains a record of the transaction and copies will be provided upon request. | SEC |
| 2026-02-23 | 2026-02-23 | Durkin Bryan T | Director | $1.3M | S — Open-market saleForm 4 footnoteF1 On February 23, 2026, Mr. Durkin sold an aggregate of 4,200 shares of CME Group Class A common stock. For reporting purposes, the sale prices within $1 range have been aggregated and the weighted average has been reported. The price range was $309.25 to $310.07. The Company maintains a record of the transaction and copies will be provided upon request. | SEC |
| 2026-03-17 | 2026-03-19 | Marcus Jonathan L | Sr MD General Counsel | $1.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This transaction was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 18, 2025. | SEC |
| 2026-03-06 | 2026-03-09 | Cook Elizabeth A | Director | $320k | S — Open-market sale Indirect holding, through: by Trust | SEC |
| 2025-11-03 | 2025-11-04 | Ford Harold Eugene Jr. | Director | $264k | S — Open-market saleForm 4 footnoteF1 On November 3, 2025, Mr. Ford sold an aggregate of 1,000 shares of CME Group Class A common stock. For reporting purposes, the sale prices within $1 range have been aggregated and the weighted average has been reported. The price range was $263.21 to $263.68. The Company maintains a record of the transaction and copies will be provided upon request. | SEC |
| 2026-02-06 | 2026-02-09 | Suskind Dennis | Director | $224k | S — Open-market sale | SEC |
| 2026-09-14 | 2026-09-14 | Cook Elizabeth A | Director | $140k | S — Open-market sale Indirect holding, through: by Trust | SEC |
| 2025-09-18 | 2025-09-18 | Marcus Jonathan L | Sr MD General Counsel | $103k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This transaction was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 18, 2025 | SEC |
| 2025-09-16 | 2025-09-17 | Mccourt Timothy Francis | Sr MD Global Head Equity & FX | $98k | S — Open-market saleForm 4 footnoteF2 Mr. McCourt surrendered shares to the Company in order to fulfill tax withholding obligations upon the vesting of restricted stock on September 16, 2025. | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Aug 26, 2025 and Sep 28, 2026, CME Group Inc. open-market activity adds up to 5 purchases worth $740k and 17 sales worth $33.6M. The net balance is $32.9M on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like CME Group Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| A | Grant or award | 52 | $68.6M |
| F | Tax withholding (shares surrendered for taxes) | 52 | $25.8M |
| S | Open-market sale | 17 | $33.6M |
| J | Other transaction (explained in the filing) | 8 | $0 |
| P | Open-market purchase | 5 | $740k |
| G | Gift | 2 | $0 |
| Total | Everything filed in the period | 136 | $128.8M |
10 of the 136 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 31 distinct people or entities have filed CME Group Inc. transactions: 1 bought on the open market and 12 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 12 who sold on the open market (17 sales in all), the three biggest sellers account for $26.5M of the $33.6M: 79% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Duffy Terrence A | Chairman and CEO | 8 | — | $21.3M (3) | 2026-09-17 |
| Cutinho Sunil | Chief Information Officer | 9 | — | $3.2M (1) | 2026-09-17 |
| Sammann Derek | Sr MD Gl Hd Commodities Mkts | 13 | — | $2.0M (1) | 2026-09-17 |
| Piell Hilda Harris | Sr MD & Chief HR Officer | 7 | — | $1.8M (1) | 2026-05-19 |
| Vroman Ken | Chief Transformation Officer | 9 | — | $1.6M (1) | 2026-09-17 |
| Durkin Bryan T | Director | 2 | — | $1.3M (1) | 2026-06-29 |
| Marcus Jonathan L | Sr MD General Counsel | 8 | — | $1.3M (3) | 2026-03-19 |
| Shepard William R | Director | 8 | $740k (5) | — | 2026-09-28 |
Shown here are the 8 who moved the most money, out of 31. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Sep 2025: 1 purchase and 3 sales, worth $371k. 6 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 1 | $3.2M |
| Sep 2025 | 1 | $73k | 3 | $299k |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 2 | $2.2M |
| Dec 2025 | 1 | $73k | 1 | $6.7M |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 3 | $1.6M |
| Mar 2026 | 1 | $437k | 3 | $3.0M |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 2 | $12.2M |
| Jun 2026 | 1 | $78k | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 0 | $0 |
| Sep 2026 | 1 | $79k | 2 | $4.3M |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
CME Group Inc. (CME) analysis page →
Other Financial Services companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
2 of the 15 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. CME's 5 open-market purchases (code P) are the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Sep 28, 2026, and a Form 4 arrives up to two business days after the trade.
15 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.